Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies underscore continuing role of demographic factors and comorbidities in blood cancer treatment and research.
Novel treatment relies on a newer form of CRISPR gene-editing technology called base editing.
NIH-funded research links alterations to inflammatory protein, underscores vaccine importance.
Potential cure strategy builds on unexpected findings about hematopoietic stem cells.
New data strongly suggest that axi-cel, as this CAR T-cell therapy is often called, can offer real hope for these lymphoma patients.
The experimental drug motixafortide helps blood-forming stem cells move from a person’s bone marrow into the bloodstream.
Researcher Rachel Lex seeks to understand why certain regions of tissue tend to develop tumors more frequently.
Wanda Zimmer, 67, a retired flight attendant, lives in Newport Beach, California. She has chronic lymphocytic leukemia (CLL).
Watch groundbreaking scientists share their experiences and explain how Damon Runyon funding makes a difference in cancer research.
A new study clarifies the benefits and risks of treatments for those with multiple myeloma, a blood cancer more common in Black Americans.
The new—and free—computational tool, CoSpar, integrates two sources of data about a cell.
New discoveries may show a way to save bone marrow cells and blood stem cells following chemotherapy.
New guidelines from NCCN offer clarity and consensus on how best to address and treat a common side effect of stem cell transplants.
Despite being the only current cure for MDS, transplants generally haven’t been offered to older patients.
To find a better FTO-targeting drug, researchers searched a collection of 260,000 chemicals housed by NCI.
The goal is to “make customizable stem cell products that could be adapted to any particular patient.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.